ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
Densy
|
110 |
22K |
23 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
110
|
22K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
Densy
|
110 |
22K |
28 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
110
|
22K
|
28
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
495 |
112K |
21 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
495
|
112K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
Densy
|
52 |
8.0K |
30 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
52
|
8.0K
|
30
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
Densy
|
110 |
22K |
13 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
110
|
22K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
Densy
|
110 |
22K |
45 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
110
|
22K
|
45
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
495 |
112K |
26 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
495
|
112K
|
26
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
495 |
112K |
16 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
495
|
112K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
495 |
112K |
29 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
495
|
112K
|
29
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
495 |
112K |
10 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
495
|
112K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
495 |
112K |
20 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
495
|
112K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
495 |
112K |
14 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
495
|
112K
|
14
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
495 |
112K |
13 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
495
|
112K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Densy
|
86 |
20K |
14 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Densy
|
86 |
20K |
29 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Densy
|
86 |
20K |
18 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Densy
|
86 |
20K |
11 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
495 |
112K |
8 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
495
|
112K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Densy
|
495 |
112K |
23 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
495
|
112K
|
23
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
358K |
47 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
1.4K
|
358K
|
47
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
Densy
|
250 |
62K |
19 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
250
|
62K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
Densy
|
250 |
62K |
46 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
250
|
62K
|
46
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
Densy
|
239 |
63K |
34 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
239
|
63K
|
34
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
Densy
|
239 |
63K |
85 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
239
|
63K
|
85
|
|
ASX - By Stock
|
PAA |
Corporate action
|
|
Densy
|
239 |
63K |
65 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
239
|
63K
|
65
|
|
ASX - By Stock
|
PAA |
Re:
Top PAAO Holders Movements as at 30 April 2024
|
|
Densy
|
4 |
1.6K |
1 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
4
|
1.6K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Densy
|
104 |
20K |
9 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
104
|
20K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
358K |
32 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
1.4K
|
358K
|
32
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust makes Head of Manufacturing appointment
|
|
Densy
|
37 |
9.4K |
20 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
37
|
9.4K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
Densy
|
317 |
82K |
19 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
317
|
82K
|
19
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
358K |
36 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
1.4K
|
358K
|
36
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
358K |
29 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
1.4K
|
358K
|
29
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
Densy
|
222 |
47K |
3 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
222
|
47K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
17K |
14 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
17K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
17K |
29 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
17K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
17K |
20 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
17K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
17K |
7 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
17K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
17K |
23 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
17K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Top 200 PAA Shareholders as at 28 March 2024
|
|
Densy
|
55 |
15K |
1 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
55
|
15K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
17K |
32 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
17K
|
32
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Media clarification
|
|
Densy
|
62 |
17K |
17 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
62
|
17K
|
17
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Densy
|
1.4K |
358K |
41 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
1.4K
|
358K
|
41
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
Densy
|
126 |
32K |
14 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
126
|
32K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
Densy
|
126 |
32K |
25 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
126
|
32K
|
25
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
Densy
|
317 |
82K |
35 |
17/03/24 |
17/03/24 |
ASX - By Stock
|
317
|
82K
|
35
|
|
ASX - By Stock
|
PAA |
Re:
Big Pharma buyouts.
|
|
Densy
|
39 |
9.5K |
11 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
9.5K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Big Pharma buyouts.
|
|
Densy
|
39 |
9.5K |
22 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
9.5K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Amylyx class action Relyvrio
|
|
Densy
|
58 |
15K |
42 |
09/03/24 |
09/03/24 |
ASX - By Stock
|
58
|
15K
|
42
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
Densy
|
77 |
20K |
16 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
77
|
20K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
Densy
|
317 |
82K |
5 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
317
|
82K
|
5
|
|